Peanut Consumption on Cognitive, Weight, and Inflammation
NCT06127511, Not applicable, Completed, University of Barcelona
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Peanut Consumption on Cognitive, Weight, and Inflammation | ClinicalTrials.gov |
| NCT number | NCT06127511 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 142 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Barcelona | ClinicalTrials.gov |
| Conditions | Cognitive Performance, Inflammation, Weight Change, Body, Adolescents | ClinicalTrials.gov |
| Interventions | Food (peanut) | ClinicalTrials.gov |
| First posted | 2023-11-13 | ClinicalTrials.gov |
| Last updated | 2026-09-04 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in the depression score in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure depression score, the CDI Childhood Depression Inventory test will be used. | ClinicalTrials.gov |
| Primary | Changes in the ability to concentrate, selective attention and processing speed in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure the ability to concentrate, selective attention and processing speed, the d2-R Attention Test (Revised) will be used. | ClinicalTrials.gov |
| Primary | Changes in assessment of interference and cognitive control in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure the assessment of interference and cognitive control, the Stroop test will be used. | ClinicalTrials.gov |
| Primary | Changes in processing speed, attention span and working memory in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure processing speed, attention span and working memory, the WISC-V Digits and Codes Subtest will be used. | ClinicalTrials.gov |
| Primary | Changes in attention and inductive reasoning in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure in attention and inductive reasoning, the Raven-2 test will be used. | ClinicalTrials.gov |
| Primary | Changes in Social cognition (emotion recognition and theory of mind) in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure Social cognition (emotion recognition and theory of mind), the NEPSY-II subtest will be used. | ClinicalTrials.gov |
| Primary | Changes in pro- and anti-inflammatory biomarkers after a daily intake of peanuts in healthy young adolescents. | Baseline and after 6 months | Cytokines (pg/mL), Monocyte chemoattractant protein-1 (MCP-1) (pg/mL), interleukin (IL)-6 and 10 (pg/mL), (mg/dL) will be assayed by immunoenzymatic methods. | ClinicalTrials.gov |
| Primary | Changes in vascular biomarkers after a daily intake of peanuts in healthy young adolescents. | Baseline and after 6 months | sVCAM-1 and sICAM-1 (ug/mL) will be assayed by immunoenzymatic methods. | ClinicalTrials.gov |
| Primary | Changes in adiposity molecules after a daily intake of peanuts in healthy young adolescents | Baseline and after 6 months | Adiponectin and adipsin (ug/mL), leptin (pg/mL), ghrelin (pg/mL), visfatin (pg/dL), resistin (pg/mL), insulin (pg/mL), glucagon (pg/dL), peptid C (pg/mL) and, PAI-1 (pg/mL) will be assayed by immunoenzymatic methods. | ClinicalTrials.gov |
| Primary | Changes in body mass index after a daily intake of peanuts in healthy young adolescents | Baseline, 3 and after 6 months | Body mass index (kg/m\^2) are calculated after measure weight (kg) and height (meter). | ClinicalTrials.gov |
| Secondary | Changes in waist circumference after a daily intake of peanuts in healthy young adolescents | Baseline, 3 and after 6 months | Change in waist circumference (cm) will be measured in triplicate | ClinicalTrials.gov |
| Secondary | Changes in blood pressure after a daily intake of peanuts in healthy young adolescents | Baseline, 3 and after 6 months | Systolic and diastolic blood pressure (mmHg) will be measured using an automatic blood pressure monitor in triplicate. | ClinicalTrials.gov |
| Secondary | Changes in heart rate after a daily intake of peanuts in healthy young adolescents | Baseline, 3 and after 6 months | Heart rate (bpm) is measured with an automatic monitor in triplicate. | ClinicalTrials.gov |
| Secondary | Changes in lipidic profile after a daily intake of peanuts in healthy young adolescents | Baseline and after 6 months | Total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides (mg/dL) will be measured using a portable Cardiocheck analyzer, through 40 µL of capillary and fasting blood. | ClinicalTrials.gov |
| Secondary | Changes in blood glucose after a daily intake of peanuts in healthy young adolescents | Baseline and after 6 months | Fasting blood glucose (mg/dL) will be measured using a portable Cardiocheck analyzer | ClinicalTrials.gov |
| Secondary | Changes in nutrients and energy intake after regular peanut in healthy young adolescents | Baseline and after 6 months | Dietary changes will be evaluated using a 151-item semi-quantitative food frequency questionnaire (Fernández-Ballart et al., 2010). | ClinicalTrials.gov |
| Secondary | Changes in physical activity after regular peanut in healthy young adolescents | Baseline and after 6 months | To study the association between changes in physical activity and changes in adiposity parameters . Actigraph wGT3X-BT accelerometers that allow the registration of the amount and intensity of physical activity will be used during 7 days per evaluation time-point. To complete this information a diary with questions about the type of physical activity performed during the 7 days will be collected. A validated questionnaire will be also used to assess physical activity habits (Barbosa et al., 2007). | ClinicalTrials.gov |
| Secondary | Changes in sleep quality after regular peanut in healthy young adolescents | Baseline and after 6 months | To study the association between changes in sleep quality and changes in adiposity parameters . Actigraph wGT3X-BT accelerometers that allow the registration of the amount and intensity of physical activity will be used during 7 days per evaluation time-point. To complete this information a diary with questions about the type of physical activity performed during the 7 days will be collected. | ClinicalTrials.gov |
| Secondary | Pubertal changes in healthy young adolescents after a daily intake of peanuts. | Baseline and after 6 months | To measure pubertal changes, the Tanner's Pubertal scale self-assessment questionnaire will be used. | ClinicalTrials.gov |
| Secondary | Changes in the gut microbiota after a daily intake of peanuts in fecal samples of healthy young adolescents. | Baseline and after 6 months | Fecal samples will be collected by the volunteers using a system for easy self-collection and stabilization of microbial DNA for gut microbiome profiling (OMNIgene - GUT). The genomic DNA will be extracted from fecal samples using the DNeasy PowerSoil Kit. Then, the 16s metagenomic analysis will be performed. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)